ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended September 30, 2025, highlighting a 230% year-over-year increase in licensing revenue to approximately USD 1.28 million, compared to USD 0.39 million in the same period of 2024. Total assets surged 181% to USD 21.18 million as of September 30, 2025, from USD 7.54 million at the end of 2024, according to a press release issued by the company.
The significant asset growth was fueled by strategic real-asset investments in Taiwan, including two land acquisitions totaling approximately USD 11 million during the third quarter. AiBtl BioPharma Inc., a subsidiary, acquired land in Puli (Nantou) for USD 7.67 million to develop a plant factory for botanical raw materials and new drug substance research. Separately, ABVC BioPharma purchased land in Longtan (Taoyuan) for USD 3.3 million for agricultural R&D and active pharmaceutical ingredient (API) cultivation. These investments, together with the planned Vitargus® GMP manufacturing facility, are expected to strengthen the company's Asia-based production and research capabilities. Property and equipment (net) rose to USD 12.06 million, up from USD 0.51 million at the end of 2024, reflecting a growth of approximately 2,100%.
ABVC continues to develop its dual-core operations between Silicon Valley, focusing on innovation and clinical development through its BioKey platform, and Taiwan, which supports manufacturing and development activities. The company maintains multiple licensing agreements covering its pipeline in central nervous system (CNS), ophthalmology, and oncology/hematology indications, each providing potential future milestone and royalty income based on development and commercialization progress.
"Our third-quarter results reflect continued progress in both our licensing revenue and asset development activities," said Dr. Uttam Patil, ABVC's Chief Executive Officer. "We remain focused on executing our strategic priorities to create sustainable value for our shareholders over the long term."
ABVC BioPharma is a clinical-stage company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. The company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
Forward-looking statements in the press release are subject to risks and uncertainties, including those related to manufacturing, financing, competition, and regulatory approvals. More detailed information is available in the company's filings with the Securities and Exchange Commission (SEC) at http://www.sec.gov.
